Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.41 |
| ▸ | DHODH | Q02127 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206014 | 0.93 | FFAR1 (0.42) | FFAR1PPARDSTIM1ORAI1 | |
| SCHEMBL17615395 | 0.92 | FFAR1 (0.41) | FFAR1DHODHPPARDSLC22A12SLC16A3 | |
| SCHEMBL17614595 | 0.91 | FFAR1 (0.34) | FFAR1PPARDSLC22A12 | |
| SCHEMBL16206009 | 0.91 | FFAR1 (0.37) | FFAR1PPARDSTIM1ORAI1SLC22A12 | |
| SCHEMBL17615190 | 0.90 | HDAC4 (0.43) | FFAR1PPARDSLC22A12SLC16A3SLC16A1 | |
| SCHEMBL16206146 | 0.90 | SLC22A12 (0.42) | FFAR1PPARDSLC22A12SLC16A3SLC16A1 | |
| SCHEMBL17614598 | 0.88 | ANO1 (0.40) | FFAR1STIM1ORAI1 | |
| SCHEMBL17614599 | 0.88 | GYS1 (0.40) | FFAR1STIM1ORAI1 | |
| SCHEMBL17614597 | 0.87 | GYS1 (0.37) | FFAR1 | |
| SCHEMBL16206012 | 0.87 | FFAR1 (0.37) | FFAR1STIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990404-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-05-27 | — | — | EP | disclosed |
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| WO-2014175465-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | 住友化学株式会社 (JP) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | FFAR1 1688/4885DHODH 2715/4885PPARD 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.